Celldex Therapeutics Inc (NASDAQ: CLDX) stock closed at $29.35 on 11/6/23 after a major increase of 13.0%. Relative to the market the stock has been weak over the last nine months but has risen 29.8% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, CLDX is expected to be Value Creation neutral.
Celldex Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Celldex Therapeutics has a poor Power Rating of 18 and a very low Appreciation Score of 4, with the Lowest Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment